Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-Seq for FOXA2 in PC3 cell line with GSK treatment and VEH control

ABSTRACT: ChIP-Seq for FOXA2 in PC3 cell line with GSK treatment and VEH control

PROVIDER: PRJNA627123 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11579394.fastq.gz	Fastqsanger.gz
	SRR11579395.fastq.gz	Fastqsanger.gz
	SRR11579396.fastq.gz	Fastqsanger.gz
	SRR11579397.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

ChIP-Seq for FOXA2 in PC3 cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148982 | GEO

ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

Project description:ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

| PRJNA627126 | ENA

ChIP-Seq for FOXA1 in LNCaP cell line with GSK treatment and VEH control

Project description:ChIP-Seq for FOXA1 in LNCaP cell line with GSK treatment and VEH control

| PRJNA627125 | ENA

ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control

Project description:ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control

| PRJNA627124 | ENA

GSK-inhibitor treatment in IMR32 neuroblastoma cell line

Project description:GSK-inhibitor treatment in IMR32 neuroblastoma cell line

| PRJEB4227 | ENA

GSK-3 inhibitor treatment effect on MLL leukemia cell

Project description:Human leukemia cell line RS4.11 was treated with GSK-3 inhibitor SB216763 for 20 hours. Gene expression profiling was performed to analyze genes affected by GSK-3 inhibition. Human leukemia cell line RS4.11 was grown in vitro and treated with 10 uM GSK-3 inhibitor SB216763 or solvent DMSO for 20 hours. Total RNA was extracted and microarray analysis was performed. Two controls and three inhibitor treatment samples were analyzed.

2010-05-27 | E-GEOD-19736 | biostudies-arrayexpress

ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148925 | GEO

ASNase treatment in PC3 cells

Project description:Ribosome profiling performed on control and L-Asparaginase treated PC3 cells

2016-02-17 | GSE74510 | GEO

GSK-3 inhibitor treatment effect on MLL leukemia cell

Project description:Human leukemia cell line RS4.11 was treated with GSK-3 inhibitor SB216763 for 20 hours. Gene expression profiling was performed to analyze genes affected by GSK-3 inhibition.

2010-05-01 | GSE19736 | GEO

GSK-3A and GSK-3B knockdown in AML cell lines

Project description:Gene expression data from AML cell lines, MOLM-14, U937, THP-1 and HL-60, that were infected with a scrambled control hairpin (shControl), two shRNAs directed against GSK-3B (shGSK3B_1 and shGSK3B_2), or two shRNAs directed against GSK-3A (shGSK3A_5 and shGSK3A_6). Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults. Long-term survival of patients with AML has changed little over the past decade, necessitating the identification and validation of new AML targets. Integration of genomic approaches with small-molecule and genetic-based high-throughput screening holds the promise of improved discovery of candidate targets for cancer therapy. Here, we identified a role for glycogen synthase kinase 3A (GSK-3A) in AML by performing two independent small-molecule library screens and an shRNA screen for perturbations that induced a differentiation expression signature in AML cells. GSK-3 is a serine-threonine kinase involved in diverse cellular processes including differentiation, signal transduction, cell cycle regulation, and proliferation. We demonstrated that specific loss of GSK-3A induced differentiation in AML by multiple measurements, including induction of gene expression signatures, morphological changes, and cell surface markers consistent with myeloid maturation. GSK-3AM-bM-^@M-^Sspecific suppression also led to impaired growth and proliferation in vitro, induction of apoptosis, loss of colony formation in methylcellulose, and anti-AML activity in vivo. Although the role of GSK-3B has been well studied in cancer development, these studies support a role for GSK-3A in AML. The AML cell lines, MOLM-14, U937, THP-1 and HL-60, were infected with a scrambled control hairpin (shControl), two shRNAs directed against GSK-3B (shGSK3B_1 and shGSK3B_2), and two shRNAs directed against GSK-3A (shGSK3A_5 and shGSK3A_6).

2012-02-27 | E-GEOD-35200 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data